Leah Lawrence
Leah Lawrence is a freelance health writer and editor based in Delaware.
Articles by Leah Lawrence
Here’s what they add to the treatment toolbox for hematologic malignancies.
Researchers and clinicians are attempting to make clinical trials better reflect the population of patients with MM.
Researchers presented updated data from the phase I XPORT-MF-034 trial at the Eleventh SOHO Annual Meeting.
The open-label ACE-536-MF-001 study included patient cohorts grouped by transfusion dependance and ruxolitinib therapy.
In PERSIST-2, treatment with pacritinib demonstrated a significant SVR benefit compared with the best available therapy, incl
Achieving event-free survival at 24 months using modern treatments was associated with improved OS.
Intratumoral hypoxia could be associated with CAR-T outcomes in patients with non-Hodgkin lymphoma.
The composition of T cells in patients with sMZL may affect the efficacy of T-cell-based therapies.
This single-center retrospective study looked at outcomes from 18 patients with AML treated with venetoclax plus an HMA.
The study included 59 patients with T-ALL with a median age of 20 at diagnosis.
The bispecific antibody mosunetuzumab in relapsed or refractory follicular lymphoma continues to show durable responses.
Researchers discuss how monitoring MRD in peripheral blood can aid in myeloma management.
Novel targets are under investigation in several types of hematologic malignancies.
CAR-T therapy leads to responses in most patients with aggressive B-cell lymphoma, but durable CRs only occur in a minority.
With more bispecific antibodies in development for hematologic malignancies, physicians must determine how best use them.
Experts discuss areas of progress and where more work is needed to establish a standard of care in mantle cell lymphoma.
There has been an improvement in the prognosis of older patients diagnosed with acute lymphoblastic leukemia.
Researchers have identified possible resistance mechanisms to gilteritinib plus venetoclax in patients with R/R AML.
Molecular MRD was strongly prognostic in patients with NPM1-mutated AML who received venetoclax-based non-intensive therapy.
Use of drugs with alternative modes of action may be needed to overcome persistent MRD positivity in myeloma.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.